Previous 10 | Next 10 |
NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, provide...
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces t...
NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improv...
NEW YORK and SALT LAKE CITY, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, and the University of Utah , one of the top research institutions in the United States, today announce...
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), the artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to ...
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney diseases to drive improved patient outcomes and advance value-based care, ann...
NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- The Centers for Medicaid & Medicare (CMS) announced the establishment of the Medicare Coverage of Innovative Technology (MCIT) pathway ( RIN: 0938-AT88 ), to provide a coverage pathway for Medicare beneficiaries nationwide to have fast...
NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kidney care innovators Renalytix AI (NASDAQ:RNLX, LSE:RENX) and DaVita (NYSE: DVA) are partnering on a program aimed at slowing disease progression and improving health outcomes for the nation’s estimated 37 million adults with chro...
NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announ...
NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today report...
News, Short Squeeze, Breakout and More Instantly...
RELX N.V. American Depositary Shares (Each representing One) Company Name:
RENX Stock Symbol:
NYSE Market:
98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with type 2 diabetes and chronic kidney disease stages 1-3b. Published study complements KidneyIntelX clinical utility data published at American Diabetes Associat...
NEW YORK and SALT LAKE CITY, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 2021 Wells Fargo Virtual Healthcare Conference. Renaly...
NEW YORK and SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Daniel J. Levangie to the Company’s board of directors. Mr. Levangie is also appointed as a member of the Company’s remuneration commi...